financetom
Business
financetom
/
Business
/
Direct Digital Stock Falls On Q4 Results: Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Direct Digital Stock Falls On Q4 Results: Here's Why
Mar 26, 2024 1:54 PM

Direct Digital Holdings ( DRCT ) shares are dropping after the company reported its fourth-quarter financial results after the bell Tuesday. Here's a look at the details. 

The Details: Direct Digital Holdings ( DRCT ) reported quarterly losses of 8 cents per share which missed the analyst consensus estimate of earnings of 26 cents.

The company reported quarterly sales of $41.01 million which missed the analyst consensus estimate of $65.95 million by 37.81% and represented a 33.4% increase over sales of $30.74 million from the same period last year.

“2023 was another transformational year for Direct Digital Holdings ( DRCT ), achieving remarkable year-over-year revenue growth of 76% as well as dramatic operational expansion, and impressive results for our shareholders,” commented Mark D. Walker, CEO of Direct Digital ( DRCT ).

“Although performance in the fourth quarter was not as strong as we initially expected due to proactive measures we are taking in the face of changing macro industry trends, we are confident our company is in a position to build on the successes of 2023, expand on emerging channel and inorganic growth opportunities and continue our strong revenue growth and market share gains in 2024,” added Walker.

Outlook: The company expects fiscal year 2024 revenue to be in the range of $170 million to $190 million, representing 15% year-over-year growth at the mid-point.

“We are pleased to announce our fiscal year 2024 revenue guidance of $170 million to $190 million. This range demonstrates our belief that we can continue our growth and operational optimization strategies to deliver strong performance for our shareholders this year,” Diana Diaz, CFO, said.

DRCT Price Action: According to Benzinga Pro, Direct Digital ( DRCT ) shares are down 33.04% after-hours at $17.75 at the time of publication Tuesday.

Related News: What’s Going On With MicroStrategy Stock?

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Procter & Gamble Insider Sold Shares Worth $3,089,880, According to a Recent SEC Filing
Procter & Gamble Insider Sold Shares Worth $3,089,880, According to a Recent SEC Filing
Feb 25, 2025
01:53 PM EST, 02/25/2025 (MT Newswires) -- Gary A Coombe, CEO, Grooming, on February 25, 2025, sold 18,000 shares in Procter & Gamble ( PG ) for $3,089,880. Following the Form 4 filing with the SEC, Coombe has control over a total of 23,816 common shares of the company, with 22,051 shares held directly and 1,765 controlled indirectly. SEC Filing:...
Datadog Unusual Options Activity
Datadog Unusual Options Activity
Feb 25, 2025
Investors with a lot of money to spend have taken a bullish stance on Datadog ( DDOG ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big...
MGE Energy's Q4 Earnings, Revenue Rise
MGE Energy's Q4 Earnings, Revenue Rise
Feb 25, 2025
01:46 PM EST, 02/25/2025 (MT Newswires) -- MGE Energy ( MGEE ) reported Q4 earnings Tuesday of $0.61 per diluted share, up from $0.55 per share a year earlier. A single analyst polled by FactSet expected $0.84 per share. Operating revenue for the quarter ended Dec. 31 was $171.4 million up from $164.7 million a year earlier. Analyst estimates weren't...
Eli Lilly Expands Zepbound Vial Dose Options, Cuts Weight-Loss Drug's Prices for Self-Pay Patients
Eli Lilly Expands Zepbound Vial Dose Options, Cuts Weight-Loss Drug's Prices for Self-Pay Patients
Feb 25, 2025
01:57 PM EST, 02/25/2025 (MT Newswires) -- Eli Lilly ( LLY ) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients. The pharmaceutical giant said the new 7.5-milligram and 10 mg vials are available for $499 a month under a new self...
Copyright 2023-2026 - www.financetom.com All Rights Reserved